Will the Biotech Rebound Run into Pricing Policy Obstacles?
Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of Pathfinders in Biopharma?
This episode is 13 minutes long.
When was this Pathfinders in Biopharma episode published?
This episode was published on February 27, 2024.
Can I download this Pathfinders in Biopharma episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.